Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New ultrasound method may speed up liver cancer treatment decisions

NCT ID NCT07145801

First seen Oct 31, 2025 · Last updated Jun 17, 2026 · Updated 31 times

Summary

This study tests whether contrast-enhanced ultrasound (CEUS) can more accurately show if liver cancer (HCC) has been killed by a treatment called radioembolization (TARE). Standard CT or MRI scans often take months to give a clear answer, which can delay needed retreatment. Researchers will enroll 30 patients and compare CEUS results to standard scans at 1-2 and 4-6 months after TARE. The goal is to see if CEUS can provide faster, clearer results to guide next steps.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LIVER CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University

    RECRUITING

    Philadelphia, Pennsylvania, 19107, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

The condition(s) this trial relates to.

carcinoma hepatocellular carcinoma liver and intrahepatic bile duct neoplasm liver cancer Liver Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.